SIRT1 Activation Promotes Long-Term Functional Recovery After Subarachnoid Hemorrhage in Rats.
Long-term outcome
Rats
Resveratrol
Sirtuin 1
Subarachnoid hemorrhage
Journal
Neurocritical care
ISSN: 1556-0961
Titre abrégé: Neurocrit Care
Pays: United States
ID NLM: 101156086
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
03
06
2022
accepted:
19
09
2022
medline:
7
6
2023
pubmed:
13
10
2022
entrez:
12
10
2022
Statut:
ppublish
Résumé
An increase in sirtuin 1 (SIRT1) reportedly attenuates early brain injury, delayed cerebral ischemia, and short-term neurologic deficits in rodent models of subarachnoid hemorrhage (SAH). This study investigates the effect of resveratrol, a SIRT1 activator, on long-term functional recovery in a clinically relevant rat model of SAH. Thirty male Wistar rats were subjected to fresh arterial blood injection into the prechiasmatic space and randomized to receive 7 days of intraperitoneal resveratrol (20 mg/kg) or vehicle injections. Body weight and rotarod performance were measured on days 0, 3, 7, and 34 post SAH. The neurologic score was assessed 7 and 34 days post SAH. Morris water maze performance was evaluated 29-33 days post SAH. Brain SIRT1 activity and CA1 neuronal survival were also assessed. Blood pressure rapidly increased in all SAH rats, and no between-group differences in blood pressure, blood gases, or glucose were detected. SAH induced weight loss during the first 7 days, which gradually recovered in both groups. Neurologic score and rotarod performance were significantly improved after resveratrol treatment at 34 days post SAH (p = 0.01 and 0.04, respectively). Latency to find the Morris water maze hidden platform was shortened (p = 0.02). In the resveratrol group, more CA1 neurons survived following SAH (p = 0.1). An increase in brain SIRT1 activity was confirmed in the resveratrol group (p < 0.05). Treatment with resveratrol for 1 week significantly improved the neurologic score, rotarod performance, and latency to find the Morris water maze hidden platform 34 days post SAH. These findings indicate that SIRT1 activation warrants further investigation as a mechanistic target for SAH therapy.
Sections du résumé
BACKGROUND
An increase in sirtuin 1 (SIRT1) reportedly attenuates early brain injury, delayed cerebral ischemia, and short-term neurologic deficits in rodent models of subarachnoid hemorrhage (SAH). This study investigates the effect of resveratrol, a SIRT1 activator, on long-term functional recovery in a clinically relevant rat model of SAH.
METHODS
Thirty male Wistar rats were subjected to fresh arterial blood injection into the prechiasmatic space and randomized to receive 7 days of intraperitoneal resveratrol (20 mg/kg) or vehicle injections. Body weight and rotarod performance were measured on days 0, 3, 7, and 34 post SAH. The neurologic score was assessed 7 and 34 days post SAH. Morris water maze performance was evaluated 29-33 days post SAH. Brain SIRT1 activity and CA1 neuronal survival were also assessed.
RESULTS
Blood pressure rapidly increased in all SAH rats, and no between-group differences in blood pressure, blood gases, or glucose were detected. SAH induced weight loss during the first 7 days, which gradually recovered in both groups. Neurologic score and rotarod performance were significantly improved after resveratrol treatment at 34 days post SAH (p = 0.01 and 0.04, respectively). Latency to find the Morris water maze hidden platform was shortened (p = 0.02). In the resveratrol group, more CA1 neurons survived following SAH (p = 0.1). An increase in brain SIRT1 activity was confirmed in the resveratrol group (p < 0.05).
CONCLUSIONS
Treatment with resveratrol for 1 week significantly improved the neurologic score, rotarod performance, and latency to find the Morris water maze hidden platform 34 days post SAH. These findings indicate that SIRT1 activation warrants further investigation as a mechanistic target for SAH therapy.
Identifiants
pubmed: 36224490
doi: 10.1007/s12028-022-01614-z
pii: 10.1007/s12028-022-01614-z
doi:
Substances chimiques
Resveratrol
Q369O8926L
Sirt1 protein, rat
EC 3.5.1.-
Sirtuin 1
EC 3.5.1.-
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
622-632Subventions
Organisme : NINDS NIH HHS
ID : R01 NS091603
Pays : United States
Informations de copyright
© 2022. Springer Science+Business Media, LLC, part of Springer Nature and Neurocritical Care Society.
Références
Carafa V, Rotili D, Forgione M, Cuomo F, Serretiello E, Hailu GS, Jarho E, Lahtela-Kakkonen M, Mai A, Altucci L. Sirtuin functions and modulation: from chemistry to the clinic. Clin Epigenet. 2016;8:61.
doi: 10.1186/s13148-016-0224-3
Pillarisetti S. A review of Sirt1 and Sirt1 modulators in cardiovascular and metabolic diseases. Recent Pat Cardiovasc Drug Discov. 2008;3:156–64.
pubmed: 18991791
doi: 10.2174/157489008786263989
Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem. 2004;73:417–35.
pubmed: 15189148
doi: 10.1146/annurev.biochem.73.011303.073651
Dryden SC, Nahhas FA, Nowak JE, Goustin AS, Tainsky MA. Role for human SIRT2 NAD-dependent deacetylase activity in control of mitotic exit in the cell cycle. Mol Cell Biol. 2003;23:3173–85.
pubmed: 12697818
pmcid: 153197
doi: 10.1128/MCB.23.9.3173-3185.2003
Grimm AA, Brace CS, Wang T, Stormo GD, Imai S. A nutrient-sensitive interaction between Sirt1 and HNF-1alpha regulates Crp expression. Aging Cell. 2011;10:305–17.
pubmed: 21176092
doi: 10.1111/j.1474-9726.2010.00667.x
Moynihan KA, Grimm AA, Plueger MM, Bernal-Mizrachi E, Ford E, Cras-Meneur C, Permutt MA, Imai S. Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab. 2005;2:105–17.
pubmed: 16098828
doi: 10.1016/j.cmet.2005.07.001
Imai S. Is Sirt1 a miracle bullet for longevity? Aging Cell. 2007;6:735–7.
pubmed: 17941969
doi: 10.1111/j.1474-9726.2007.00344.x
Imai S. SIRT1 and caloric restriction: an insight into possible trade-offs between robustness and frailty. Curr Opin Clin Nutr Metab Care. 2009;12:350–6.
pubmed: 19474721
pmcid: 2734391
doi: 10.1097/MCO.0b013e32832c932d
Imai S. From heterochromatin islands to the NAD World: a hierarchical view of aging through the functions of mammalian Sirt1 and systemic NAD biosynthesis. Biochim Biophys Acta. 2009;1790:997–1004.
pubmed: 19289152
pmcid: 2743781
doi: 10.1016/j.bbagen.2009.03.005
Imai S, The NAD. World: a new systemic regulatory network for metabolism and aging–Sirt1, systemic NAD biosynthesis, and their importance. Cell Biochem Biophys. 2009;53:65–74.
pubmed: 19130305
pmcid: 2734380
doi: 10.1007/s12013-008-9041-4
Imai S. “Clocks” in the NAD World: NAD as a metabolic oscillator for the regulation of metabolism and aging. Biochim Biophys Acta. 2010;1804:1584–90.
pubmed: 19897060
doi: 10.1016/j.bbapap.2009.10.024
Imai S. Dissecting systemic control of metabolism and aging in the NAD World: the importance of SIRT1 and NAMPT-mediated NAD biosynthesis. FEBS Lett. 2011;585:1657–62.
pubmed: 21550345
pmcid: 3104082
doi: 10.1016/j.febslet.2011.04.060
Imai S. A possibility of nutriceuticals as an anti-aging intervention: activation of sirtuins by promoting mammalian NAD biosynthesis. Pharmacol Res. 2010;62:42–7.
pubmed: 20085812
pmcid: 2873125
doi: 10.1016/j.phrs.2010.01.006
Imai S, Yoshino J. The importance of NAMPT/NAD/SIRT1 in the systemic regulation of metabolism and ageing. Diabetes Obes Metab. 2013;15(Suppl 3):26–33.
pubmed: 24003918
doi: 10.1111/dom.12171
Vaziri H, Dessain SK, Ng Eaton E, Imai SI, Frye RA, Pandita TK, Guarente L, Weinberg RA. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell. 2001;107:149–59.
pubmed: 11672523
doi: 10.1016/S0092-8674(01)00527-X
Ramsey KM, Mills KF, Satoh A, Imai S. Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice. Aging Cell. 2008;7:78–88.
pubmed: 18005249
doi: 10.1111/j.1474-9726.2007.00355.x
Ramsey KM, Yoshino J, Brace CS, Abrassart D, Kobayashi Y, Marcheva B, Hong HK, Chong JL, Buhr ED, Lee C, et al. Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science. 2009;324:651–4.
pubmed: 19299583
pmcid: 2738420
doi: 10.1126/science.1171641
Satoh A, Brace CS, Ben-Josef G, West T, Wozniak DF, Holtzman DM, Herzog ED, Imai S. SIRT1 promotes the central adaptive response to diet restriction through activation of the dorsomedial and lateral nuclei of the hypothalamus. J Neurosci. 2010;30:10220–32.
pubmed: 20668205
pmcid: 2922851
doi: 10.1523/JNEUROSCI.1385-10.2010
Satoh A, Stein L, Imai S. The role of mammalian sirtuins in the regulation of metabolism, aging, and longevity. Handb Exp Pharmacol. 2011;206:125–62.
pubmed: 21879449
pmcid: 3745303
doi: 10.1007/978-3-642-21631-2_7
Satoh A, Brace CS, Rensing N, Cliften P, Wozniak DF, Herzog ED, Yamada KA, Imai S. Sirt1 extends life span and delays aging in mice through the regulation of Nk2 homeobox 1 in the DMH and LH. Cell Metab. 2013;18:416–30.
pubmed: 24011076
pmcid: 3794712
doi: 10.1016/j.cmet.2013.07.013
Wang T, Zhang X, Bheda P, Revollo JR, Imai S, Wolberger C. Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme. Nat Struct Mol Biol. 2006;13:661–2.
pubmed: 16783373
doi: 10.1038/nsmb1114
Yoshino J, Conte C, Fontana L, Mittendorfer B, Imai S, Schechtman KB, Gu C, Kunz I, Rossi Fanelli F, Patterson BW, et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 2012;16:658–64.
pubmed: 23102619
pmcid: 3496026
doi: 10.1016/j.cmet.2012.09.015
Yoshino J, Mills KF, Yoon MJ, Imai S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14:528–36.
pubmed: 21982712
pmcid: 3204926
doi: 10.1016/j.cmet.2011.08.014
Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science. 2004;305:1010–3.
pubmed: 15310905
doi: 10.1126/science.1098014
Li XH, Chen C, Tu Y, Sun HT, Zhao ML, Cheng SX, Qu Y, Zhang S. Sirt1 promotes axonogenesis by deacetylation of Akt and inactivation of GSK3. Mol Neurobiol. 2013;48:490–9.
pubmed: 23475611
doi: 10.1007/s12035-013-8437-3
Qin W, Yang T, Ho L, Zhao Z, Wang J, Chen L, Zhao W, Thiyagarajan M, MacGrogan D, Rodgers JT, et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J Biol Chem. 2006;281:21745–54.
pubmed: 16751189
doi: 10.1074/jbc.M602909200
Qian C, Jin J, Chen J, Li J, Yu X, Mo H, Chen G. SIRT1 activation by resveratrol reduces brain edema and neuronal apoptosis in an experimental rat subarachnoid hemorrhage model. Mol Med Rep. 2017;16:9627–35.
pubmed: 29039533
doi: 10.3892/mmr.2017.7773
Li Z, Han X. Resveratrol alleviates early brain injury following subarachnoid hemorrhage: possible involvement of the AMPK/SIRT1/autophagy signaling pathway. Biol Chem. 2018;399:1339–50.
pubmed: 30067508
doi: 10.1515/hsz-2018-0269
Diwan D, Vellimana AK, Aum DJ, Clarke J, Nelson JW, Lawrence M, Han BH, Gidday JM, Zipfel GJ. Sirtuin 1 mediates protection against delayed cerebral ischemia in subarachnoid hemorrhage in response to hypoxic postconditioning. J Am Heart Assoc. 2021;10: e021113.
pubmed: 34622677
pmcid: 8751859
doi: 10.1161/JAHA.121.021113
Clarke JV, Brier LM, Rahn RM, Diwan D, Yuan JY, Bice AR, Imai SI, Vellimana AK, Culver JP, Zipfel GJ. SIRT1 mediates hypoxic postconditioning- and resveratrol-induced protection against functional connectivity deficits after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2022;42:1210–23.
pubmed: 35137611
pmcid: 9207494
doi: 10.1177/0271678X221079902
Vellimana AK, Aum DJ, Diwan D, Clarke JV, Nelson JW, Lawrence M, Han BH, Gidday JM, Zipfel GJ. SIRT1 mediates hypoxic preconditioning induced attenuation of neurovascular dysfunction following subarachnoid hemorrhage. Exp Neurol. 2020;334: 113484.
pubmed: 33010255
pmcid: 8908895
doi: 10.1016/j.expneurol.2020.113484
Chen J, Li M, Zhu X, Chen Y, Zhang C, Shi W, Chen Q, Wang Y. Anterior communicating artery aneurysms: anatomical considerations and microsurgical strategies. Front Neurol. 2020;11:1020.
pubmed: 33013671
pmcid: 7509403
doi: 10.3389/fneur.2020.01020
Sasaki T, Hoffmann U, Kobayashi M, Sheng H, Ennaceur A, Lombard FW, Warner DS. Long-term cognitive deficits after subarachnoid hemorrhage in rats. Neurocrit Care. 2016;25:293–305.
pubmed: 26896093
doi: 10.1007/s12028-016-0250-1
Prunell GF, Mathiesen T, Diemer NH, Svendgaard NA. Experimental subarachnoid hemorrhage: subarachnoid blood volume, mortality rate, neuronal death, cerebral blood flow, and perfusion pressure in three different rat models. Neurosurgery. 2003;52:165–175; discussion 175–166
Prunell GF, Mathiesen T, Svendgaard NA. A new experimental model in rats for study of the pathophysiology of subarachnoid hemorrhage. NeuroReport. 2002;13:2553–6.
pubmed: 12499866
doi: 10.1097/00001756-200212200-00034
Prunell GF, Mathiesen T, Svendgaard NA. Experimental subarachnoid hemorrhage: cerebral blood flow and brain metabolism during the acute phase in three different models in the rat. Neurosurgery. 2004;54:426–436; discussion 427–436
Takata K, Sheng H, Borel CO, Laskowitz DT, Warner DS, Lombard FW. Simvastatin treatment duration and cognitive preservation in experimental subarachnoid hemorrhage. J Neurosurg Anesthesiol. 2009;21:326–33.
pubmed: 19955895
doi: 10.1097/ANA.0b013e3181acfde7
Parra A, McGirt MJ, Sheng H, Laskowitz DT, Pearlstein RD, Warner DS. Mouse model of subarachnoid hemorrhage associated cerebral vasospasm: methodological analysis. Neurol Res. 2002;24:510–6.
pubmed: 12117325
doi: 10.1179/016164102101200276
Takata K, Sheng H, Borel CO, Laskowitz DT, Warner DS, Lombard FW. Long-term cognitive dysfunction following experimental subarachnoid hemorrhage: new perspectives. Exp Neurol. 2008;213:336–44.
pubmed: 18625221
doi: 10.1016/j.expneurol.2008.06.009
Buunk AM, Groen RJM, Veenstra WS, Metzemaekers JDM, van der Hoeven JH, van Dijk JMC, Spikman JM. Cognitive deficits after aneurysmal and angiographically negative subarachnoid hemorrhage: Memory, attention, executive functioning, and emotion recognition. Neuropsychology. 2016;30:961–9.
pubmed: 27195987
doi: 10.1037/neu0000296
Beeckmans K, Crunelle CL, Van den Bossche J, Dierckx E, Michiels K, Vancoillie P, Hauman H, Sabbe B. Cognitive outcome after surgical clipping versus endovascular coiling in patients with subarachnoid hemorrhage due to ruptured anterior communicating artery aneurysm. Acta Neurol Belg. 2020;120:123–32.
pubmed: 31745846
doi: 10.1007/s13760-019-01245-w
Buunk AM, Spikman JM, Metzemaekers JDM, van Dijk JMC, Groen RJM. Return to work after subarachnoid hemorrhage: the influence of cognitive deficits. PLoS ONE. 2019;14: e0220972.
pubmed: 31398223
pmcid: 6688815
doi: 10.1371/journal.pone.0220972
Ma N, Feng X, Wu Z, Wang D, Liu A. Cognitive impairments and risk factors after ruptured anterior communicating artery aneurysm treatment in low-grade patients without severe complications: a multicenter retrospective study. Front Neurol. 2021;12: 613785.
pubmed: 33643199
pmcid: 7907430
doi: 10.3389/fneur.2021.613785
Mohanty M, Dhandapani S, Gupta SK, Shahid AH, Patra DP, Sharma A, Mathuriya SN. Cognitive impairments after clipping of ruptured anterior circulation aneurysms. World Neurosurg. 2018;117:e430–7.
pubmed: 29920394
doi: 10.1016/j.wneu.2018.06.048
Li Y, Yang H, Ni W, Gu Y. Effects of deferoxamine on blood-brain barrier disruption after subarachnoid hemorrhage. PLoS ONE. 2017;12: e0172784.
pubmed: 28249040
pmcid: 5332094
doi: 10.1371/journal.pone.0172784
Kreiter KT, Copeland D, Bernardini GL, Bates JE, Peery S, Claassen J, Du YE, Stern Y, Connolly ES, Mayer SA. Predictors of cognitive dysfunction after subarachnoid hemorrhage. Stroke. 2002;33:200–8.
pubmed: 11779911
doi: 10.1161/hs0102.101080
Duan H, Li L, Shen S, Ma Y, Yin X, Liu Z, Yuan C, Wang Y, Zhang J. Hydrogen sulfide reduces cognitive impairment in rats after subarachnoid hemorrhage by ameliorating neuroinflammation mediated by the TLR4/NF-kappaB pathway in microglia. Front Cell Neurosci. 2020;14:210.
pubmed: 32754015
pmcid: 7381317
doi: 10.3389/fncel.2020.00210
Dong Y, Li Y, Feng D, Wang J, Wen H, Liu D, Zhao D, Liu H, Gao G, Yin Z, et al. Protective effect of HIF-1alpha against hippocampal apoptosis and cognitive dysfunction in an experimental rat model of subarachnoid hemorrhage. Brain Res. 2013;1517:114–21.
pubmed: 23608228
doi: 10.1016/j.brainres.2013.04.024
Geraghty JR, Lara-Angulo MN, Spegar M, Reeh J, Testai FD. Severe cognitive impairment in aneurysmal subarachnoid hemorrhage: Predictors and relationship to functional outcome. J Stroke Cerebrovasc Dis. 2020;29: 105027.
pubmed: 32807442
pmcid: 7438604
doi: 10.1016/j.jstrokecerebrovasdis.2020.105027
McBride DW, Blackburn SL, Peeyush KT, Matsumura K, Zhang JH. The role of thromboinflammation in delayed cerebral ischemia after subarachnoid hemorrhage. Front Neurol. 2017;8:555.
pubmed: 29109695
pmcid: 5660311
doi: 10.3389/fneur.2017.00555
Clarke JV, Suggs JM, Diwan D, Lee JV, Lipsey K, Vellimana AK, Zipfel GJ. Microvascular platelet aggregation and thrombosis after subarachnoid hemorrhage: a review and synthesis. J Cereb Blood Flow Metab. 2020;40:1565–75.
pubmed: 32345104
pmcid: 7370365
doi: 10.1177/0271678X20921974
Santos GA, Petersen N, Zamani AA, Du R, LaRose S, Monk A, Sorond FA, Tan CO. Pathophysiologic differences in cerebral autoregulation after subarachnoid hemorrhage. Neurology. 2016;86:1950–6.
pubmed: 27164675
pmcid: 4887123
doi: 10.1212/WNL.0000000000002696
Lidington D, Wan H, Bolz SS. Cerebral autoregulation in subarachnoid hemorrhage. Front Neurol. 2021;12: 688362.
pubmed: 34367053
pmcid: 8342764
doi: 10.3389/fneur.2021.688362
Sugimoto K, Chung DY. Spreading depolarizations and subarachnoid hemorrhage. Neurotherapeutics. 2020;17:497–510.
pubmed: 32323204
pmcid: 7283429
doi: 10.1007/s13311-020-00850-5
Leng LZ, Fink ME, Iadecola C. Spreading depolarization: a possible new culprit in the delayed cerebral ischemia of subarachnoid hemorrhage. Arch Neurol. 2011;68:31–6.
pubmed: 20837823
doi: 10.1001/archneurol.2010.226
Rowland MJ, Garry P, Ezra M, Corkill R, Baker I, Jezzard P, Westbrook J, Douaud G, Pattinson KTS. Early brain injury and cognitive impairment after aneurysmal subarachnoid haemorrhage. Sci Rep. 2021;11:23245.
pubmed: 34853362
pmcid: 8636506
doi: 10.1038/s41598-021-02539-x
Vellimana AK, Diwan D, Clarke J, Gidday JM, Zipfel GJ. SIRT1 Activation: a potential strategy for harnessing endogenous protection against delayed cerebral ischemia after subarachnoid hemorrhage. Neurosurgery. 2018;65:1–5.
pubmed: 31076789
pmcid: 8892594
doi: 10.1093/neuros/nyy201
Zhang XS, Wu Q, Wu LY, Ye ZN, Jiang TW, Li W, Zhuang Z, Zhou ML, Zhang X, Hang CH. Sirtuin 1 activation protects against early brain injury after experimental subarachnoid hemorrhage in rats. Cell Death Dis. 2016;7: e2416.
pubmed: 27735947
pmcid: 5133967
doi: 10.1038/cddis.2016.292
Peng Y, Jin J, Fan L, Xu H, He P, Li J, Chen T, Ruan W, Chen G. Rolipram attenuates early brain injury following experimental subarachnoid hemorrhage in rats: possibly via regulating the SIRT1/NF-kappaB pathway. Neurochem Res. 2018;43:785–95.
pubmed: 29397536
doi: 10.1007/s11064-018-2480-4
Zhao L, Liu H, Yue L, Zhang J, Li X, Wang B, Lin Y, Qu Y. Melatonin attenuates early brain injury via the melatonin receptor/Sirt1/NF-kappaB signaling pathway following subarachnoid hemorrhage in mice. Mol Neurobiol. 2017;54:1612–21.
pubmed: 26867656
doi: 10.1007/s12035-016-9776-7
Zhou XM, Zhang X, Zhang XS, Zhuang Z, Li W, Sun Q, Li T, Wang CX, Zhu L, Shi JX, et al. SIRT1 inhibition by sirtinol aggravates brain edema after experimental subarachnoid hemorrhage. J Neurosci Res. 2014;92:714–22.
pubmed: 24482345
doi: 10.1002/jnr.23359
Abozaid OAR, Sallam MW, El-Sonbaty S, Aziza S, Emad B, Ahmed ESA. Resveratrol-selenium nanoparticles alleviate neuroinflammation and neurotoxicity in a rat model of Alzheimer’s disease by regulating Sirt1/miRNA-134/GSK3beta expression. Biol Trace Elem Res. 2022;6:66.
Salehi B, Mishra AP, Nigam M, Sener B, Kilic M, Sharifi-Rad M, Fokou PVT, Martins N, Sharifi-Rad J. Resveratrol: a double-edged sword in health benefits. Biomedicines. 2018;6:66.
doi: 10.3390/biomedicines6030091
Faghihzadeh F, Hekmatdoost A, Adibi P. Resveratrol and liver: a systematic review. J Res Med Sci. 2015;20:797–810.
pubmed: 26664429
pmcid: 4652315
doi: 10.4103/1735-1995.168405